Drug Profile
Galidesivir - BioCryst Pharmaceuticals
Alternative Names: BCX-4430Latest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator Albert Einstein College of Medicine; BioCryst Pharmaceuticals; Victoria University of Wellington
- Developer BioCryst Pharmaceuticals; National Institute of Allergy and Infectious Diseases; Utah State University
- Class Antivirals; Purine nucleosides; Pyrimidine nucleosides; Pyrroles; Pyrrolidines; Small molecules
- Mechanism of Action RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections; Ebola virus infections; Marburg virus disease; Middle East respiratory syndrome coronavirus; Yellow fever; Zika virus infection